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Background: Limb revascularization in patients with end-stage renal disease (ESRD) has been criticized because of the low
rates of limb preservation and overall survival that characterize this patient population. We undertook a formal cost-
utility analysis to evaluate the role of revascularization in the ESRD population.
Methods: A probabilistic Markov model was used to simulate the clinical outcomes and long-term outcomes after six
different strategies for the management of nonhealing foot wounds in patients with critical limb ischemia and ESRD. All
scenarios considered all-cause mortality and major amputation for failure of limb salvage. Parameter estimates of the
costs, clinical events, and functional outcomes used in the model were derived from primary data or published literature.
Costs are reported in 2011 U.S. dollars.
Results: Local wound care alone had the lowest long-term total cost of the management strategies evaluated; primary
amputation had the highest. Purely endovascular intervention yielded the highest limb salvage rates. Endovascular
intervention had a cost of $15,403 per additional year of ambulation beyond that by local wound care alone. Endo-
vascular intervention had the potential for cost-savings (ie, better health beneﬁts at lower cost) only with very high 1-year
wound healing rates. The 5-year survival rates ranged from 17% to 34% in all management strategies.
Conclusions: Endovascular intervention may be a cost-effective alternative to local wound care alone for patients with
ESRD and ischemic foot wounds, but with small marginal health beneﬁts at considerable cost. Local wound care alone
may be preferable to primary amputation. (J Vasc Surg 2014;60:369-74.)Patients with end-stage renal disease (ESRD) and pe-
ripheral arterial disease (PAD) are at high risk for develop-
ment of nonhealing foot wounds.1,2 Two particular
characteristics of the ESRD patient population make at-
tempts at limb preservation through revascularization and
subsequent wound healing very challenging, however.
First, limb salvage attempts fail more frequently in the
ESRD population than in the non-ESRD critical limb
ischemia (CLI) patient population, often despite a patent
bypass graft.3-5 Second, the perioperative survival rate
and the long-term survival rate of patients with ESRD
are both signiﬁcantly lower than those of the non-ESRD
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://dx.doi.org/10.1016/j.jvs.2014.02.003uncertainty about whether efforts to achieve limb preserva-
tion are worthwhile or cost-effective in the ESRD patient
population.3,8-11
Our goal for this study was to assess the health beneﬁts
and the total costs of various strategies used to manage
PAD associated with nonhealing foot wounds (Rutherford
category 5 chronic limb ischemia12) in patients with ESRD.
Herein we describe this assessment, done in the form of a
formal cost-utility analysis.
METHODS
Overall study design and deﬁnitions. The objective
of this study was a formal assessment of the total costs
and health beneﬁts (ie, a cost-utility analysis) of strategies
for management of nonhealing ulcers associated with
severe PAD (ie, Rutherford category 5 ischemia) among
patients with ESRD who are ambulatory and indepen-
dently living at baseline. The following management stra-
tegies were considered: (1) local wound care, with selective
major amputation as indicated; (2) primary major ampu-
tation; (3) revascularization with infrainguinal surgical
bypass using an autologous vein conduit and subsequent
endovascular intervention as needed to maintain or to
restore patency of the bypass graft; (4) revascularization
with infrainguinal surgical bypass using an autologous vein
conduit and open surgical intervention as needed to
maintain or to restore patency of the bypass graft; (5) initial
revascularization with endovascular intervention with sur-
gical bypass for failure of wound healing; possible endo-
vascular revisions as needed for failure of the initial
endovascular intervention; and (6) revascularization ach-
ieved purely through an initial endovascular intervention,369
Table I. Comparison of important parameters that were
modiﬁed from the initial model of the general critical
limb ischemia (CLI) patient population (see review13)
to simulate an end-stage renal disease (ESRD) patient
population
Parameter
General CLI
population, %
ESRD
population, %
Clinical events
Annual (baseline) mortality 11.8 21.0
Additional perioperative
mortality rate associated with
Major amputation 3.9 16.4
Surgical bypass 2.6 10.8
Endovascular intervention 2.6 8.1
One-year limb salvage rate
associated with
Local wound care 62.9 54.5
Surgical bypass 89.2 78.6
Endovascular intervention 89.2 78.6
Annual rate of major amputation
during ﬁrst year after
Local wound care 38.0 27.9-48.1
Surgical bypass 2.6 2.0-3.0
Endovascular intervention 2.6 2.0-3.0
Functional outcomes
Proportion remaining
ambulatory at 1 year after
Major amputation 55.5 37.9
Surgical bypass 97.1 75.7
Endovascular intervention 97.1 75.7
Proportion remaining
independent at 1 year after
Major amputation 92.0 63.8
Surgical bypass 98.6 80.4
Endovascular intervention 98.6 80.4
The full range of values used in the probabilistic model was determined by
various distributions, which included beta, gamma, and triangular.
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needed.
Clinical parameters used. The clinical parameters
used in this study were based primarily on those identiﬁed
in our background research and in the initial Model to
Optimize Value in Ischemic Extremities (MOVIE)
study.13,14 Certain clinical parameter estimates were then
modiﬁed to simulate outcomes speciﬁc to a patient popu-
lation with PAD and ESRD. In general, estimates were
obtained from studies speciﬁcally of ESRD patients with
PAD and Rutherford category 5 limb ischemia whenever
possible. When these were not available, studies of ESRD
patients with PAD undergoing revascularization for CLI
(either ischemic rest pain [Rutherford category 4]
or nonhealing wounds [Rutherford category 5]) were used.
No randomized studies speciﬁc to the ESRD/PAD
population were identiﬁed; we therefore relied on meta-
analyses of single-center studies, multi-institution obser-
vational studies, and data from large clinical databases
(including data from the Vascular Study Group of New
England [VSGNE] and the American College of Surgeons
National Surgical Quality Improvement Project) to the
extent possible. Data from single-institution observational
studies were used only when estimates were not available
from meta-analyses or multi-institution studies.
Numerous changes were made to the clinical estimates
used in the general Rutherford category 5 patient popula-
tion in the initial MOVIE study to reﬂect the clinical out-
comes of a patient population with ESRD, severe PAD,
and nonhealing foot wounds (Table I). All of the revised
clinical outcome parameters were based on previously pub-
lished studies of revascularization or foot ulcer outcomes in
patients with ESRD and CLI. Speciﬁcally:
d Annual baseline mortality rate was increased from 12%
to 21% to simulate the survival rates of 53% at 2 years
and 28% at 5 years reported by Albers et al.6
d The perioperative mortality rate for surgical revascular-
ization was increased from the 2.6% reported in the
Bypass vs Angioplasty in Severe Ischaemia of the Leg
(BASIL) trial to 10.8% as reported by Gajdos et al.7
The periprocedural mortality rate for endovascular
intervention was estimated to be 75% of this, or
8.1%. The perioperative mortality rate of major am-
putation was estimated as 16.1% on the basis of esti-
mates from a risk-adjusted study of the perioperative
mortality for surgical revascularization and primary
amputation.15
d The 1-year limb salvage rate for endovascular interven-
tion and surgical revascularization was decreased from
90% to 79% as reported by Albers et al.6 When patients
who died within the ﬁrst year after having undergone
revascularization and subsequent major amputation
were included, this reﬂects a total major amputation
rate of 33% during the initial year, increased from the
11% rate used in the initial MOVIE study. The major
amputation rate beyond the ﬁrst year after revasculari-
zation was increased from 3% to 6% per year.6d The probability of remaining ambulatory after revascu-
larization was decreased from 97%16,17 to 76% on the
basis of data of ESRD patients undergoing revascular-
ization from the VSGNE.18
d The probability of independence (ie, maintaining the
ability to live independently) after revascularization
was decreased from 98%17 to 64% on the basis of the
VSGNE data,18 and the proportion of patients needing
a temporary stay in a skilled nursing facility after revas-
cularization was increased from 29% to 38% on the
basis of the VSGNE data.18
d The 1-year wound healing rate after a successful (pat-
ent) surgical and endovascular revascularization was
decreased from 95% and 60%, respectively, to 50%
and 50% on the basis of single-center reports by John-
son3 and Aulivola.19
d The probability of remaining ambulatory after major
(transtibial or transfemoral) amputation was decreased
from 55%13 to 38%.20 An additional deterministic
sensitivity analysis was performed in which this proba-
bility was maintained at 55%.
d The 1-year wound healing rate with local wound care
alone was decreased from 41% to 20%. The 1-year
Table II. Projected clinical outcomes, health beneﬁts, and costs of various strategies used to manage peripheral arterial
disease (PAD) with nonhealing foot wounds (Rutherford category 5 ischemia) in a population with end-stage renal
disease (ESRD)
Strategy
Median 5-year
survival, %
Median 5-year
limb salvage, %
Median years
of ambulation
Median total costs,
2011 U.S. dollars
Wound care alone (strategy 1) 26.4 14.1 1.71 118,086
Primary amputation (strategy 2) 24.4 0 1.19 152,426
Initial endovascular intervention;
repeated interventions as needed
(strategy 5)
25.4 65.0 1.93 121,478
Initial endovascular intervention;
surgical bypass 6 revisions as needed
for failure (strategy 6)
24.9 65.2 1.87 124,696
Initial surgical bypass; surgical revisions
as needed (strategy 3)
24.4 65.0 1.82 128,517
Initial surgical bypass; endovascular
revisions as needed (strategy 4)
24.4 65.0 1.82 126,487
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increased from 61% to 80%, and the major amputation
rate at 1 year was increased from 38% to 50% on the
basis of a large review by Gershater.21
The total (direct and indirect) inpatient costs used in
the model were based on previous work by our group.14
We used previously published outpatient cost estimates.13
All cost estimates (obtained in 2009 U.S. dollars) were
converted to 2011 U.S. dollars on the basis of inﬂation
data from the U.S. Bureau of Labor Statistics.
Model design and analysis. A probabilistic Markov
model was used to formally assess the relationship between
long-term total costs and health beneﬁts. A 10-year time
horizon was used to balance the lifetime time horizon
typically recommended for cost-utility analyses22 with both
the limited survival that characterizes this patient popula-
tion and the dearth of clinical parameter estimates
extending past 5 years. The analysis was performed with
1000 trials of cohorts having 1000 hypothetical patients. In
brief, hypothetical patients with ESRD and Rutherford
category 5 CLI (foot wounds associated with signiﬁcant
PAD) entered the model at time zero and underwent one
of the management strategies mentioned before. All pa-
tients were at risk for limb loss and all-cause mortality at
any point in time. Patients progressed through various
clinical states for 10 years unless death occurred before this
time point. Differential costs and health beneﬁts were tal-
lied throughout this time period (Supplementary Fig,
online only). Costs and utilities were discounted at a
standard 3.5% annual rate.22 The cost (in 2011 U.S. dol-
lars) of providing one additional year of ambulatory ability
(ie, 1 year of ambulation) beyond that provided by local
wound care alone (strategy 1) was the primary cost-utility
analysis in this study; this was measured by incremental
cost-effectiveness ratios (ICERs).23 Median survival times
and total costs were calculated secondary end points.
Quality-adjusted life-years was not an end point used in
analyses of this study. Deterministic sensitivity analysesdsequential analyses in which a parameter is varied over a set
(determined) rangedwere used to investigate the inﬂuence
of certain variables on overall costs and health beneﬁts.23
RESULTS
Base case scenario: clinical outcomes, health bene-
ﬁts, costs, and ICERs. The median 5-year survival rates
for the six management strategies were 24.4% to 26.4%
over the 1000 trials, with an interquartile range of 22.7% to
27.9% among the strategies (Table II). This corresponded
to median survival times of 2.4 years for the bypass and
primary amputation management strategies, 2.5 years for
the endovascular-ﬁrst management strategies, and 2.7 years
for the wound care strategy. The median 5-year limb
salvage rates ranged from 64.8% to 65.2% for the revas-
cularization strategies (strategies 3-6) over the 1000 trials,
with interquartile ranges of 57.9% to 75.6% for these
strategies. The median 5-year limb salvage rate for local
wound care (strategy 1) was 14.1% with an interquartile
range of 12.6% to 15.2%.
The median number of ambulatory years is listed in
Table II. The endovascular strategies (strategies 3 and 4)
had the highest median ambulatory years, followed by
the surgical revascularization strategies (strategies 5 and
6) and local wound care (strategy 1). Primary amputation
(strategy 2) had the lowest median ambulatory years
(Table II). Thus, in a cost-utility analysis of cost per addi-
tional year of ambulation, purely endovascular intervention
(strategy 5) had an ICER of $15,403 per additional year of
ambulation over local wound care alone (strategy 1) (Fig).
Initial endovascular intervention with surgical bypass for
failures (strategy 6) had an ICER of $40,594 per additional
year of ambulation over local wound care alone (strategy 1).
The surgical bypass strategies (strategies 3 and 4) produced
very small marginal beneﬁts above local wound care at
much higher costs, resulting in ICERs for each of these
strategies that exceeded $70,000 per additional year of
ambulation. Primary amputation (strategy 2) was both
more costly and less beneﬁcial than local wound care
Fig. Scatterplot comparing the differences in long-term total costs (x-axis) and differences in median ambulatory
years (y-axis) between purely endovascular intervention (strategy 5) and local wound care alone (strategy 1) in the base
case scenario.
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effectiveness analyses).
Deterministic sensitivity analyses. The base case sce-
nario assumed the probability of ambulation after a major
(above-ankle) amputation to be lower in the ESRD popu-
lation than in the general CLI population (see Methods). A
deterministic sensitivity analysis was done to assess the
impact of assuming the probability of ambulation to be
no different in the ESRD and general CLI populations.
In this analysis, local wound care (strategy 1) and endovas-
cular intervention (strategy 5) both resulted in 2.0 median
years of ambulatory ability, higher than all remaining
strategies. As local wound care had a lower total cost
($50,807 vs $93,278) in this scenario, the management
strategy of local wound care appears to dominate (ie, pro-
vide at least as much health beneﬁts at lower total costs) all
other management strategies as the probability of success-
ful ambulation with a limb prosthesis of this patient popu-
lation approaches that of the general PAD/CLI patient
population.
An additional deterministic sensitivity analysis was per-
formed to evaluate the impact of improved wound healing
rates after surgical revascularization. Surgical revasculariza-
tion did not approach cost-effectiveness or cost-savings at
any wound healing rate. The ICER of endovascular inter-
vention decreased as the 1-year wound healing rate
increased; cost-savings (ie, improved health beneﬁts at
lower cost) was achieved when the wound healing rate
exceeded 65% at 1 year.
DISCUSSION
In a previous study, we found surgical bypass to be the
most cost-effective alternative to local wound care forpatients with PAD and nonhealing wounds of the foot
(Rutherford category 5 chronic limb ischemia). As this pre-
vious analysis was based on a general CLI population
similar to that in the Project of Ex-Vivo vein graft Engi-
neering via Transfection III (PREVENT III) trial, it
assumed a population with an approximately 12% incidence
of ESRD. Compared with the typical CLI patient, howev-
er, ESRD patients with nonhealing foot wounds have long
been recognized as having a clinical problem that is espe-
cially challenging to resolve. Indeed, the higher periopera-
tive mortality rate, the low long-term survival rate, and the
high rate of progression to amputationdoften despite a
patent bypass graftdhave led some previous authors to
suggest primary amputation as the best management op-
tion for patients with ESRD, PAD, and nonhealing foot
wounds or gangrene.3,8-10
The results of the current analysis suggest that local
wound care and endovascular intervention would be op-
tions that are more cost-effective than primary amputation.
Consistent with ﬁndings from the BASIL trial,24,25 endo-
vascular intervention may be preferable to surgical revascu-
larization because of the limited survival seen in this patient
population. In a report of their experiences with endovas-
cular intervention for patients with ESRD, Aulivola et al re-
ported results comparable to those projected by our model.
In particular, although the overall technical success rate was
high, four of 15 (27%) required repeated intervention.
Only four of 14 (29%) receiving purely endovascular inter-
vention healed, whereas three (21%) remained unhealed
and seven (50%) eventually proceeded to major amputa-
tion. Indeed, the one previous cost-effectiveness analysis
and previous studies or reviews with commentary all appear
to be consistent with the results of our study in suggesting
JOURNAL OF VASCULAR SURGERY
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ulation are poor but that revascularization seems to provide
beneﬁt over primary amputation.9-11,26
In our analysis, endovascular intervention was the most
cost-effective alternative to local wound care. Although it
may be an acceptable alternative, we note that this strategy
for revascularization is much more expensive and much less
beneﬁcial in the ESRD patient population than in the
general CLI population. Speciﬁcally, the median projected
long-term (10-year) total cost of endovascular intervention
was $89,040 in the general CLI population14 and
$121,478 in the ESRD population of this study. In the
general CLI population, endovascular intervention pro-
duced a median of 4.62 years of ambulatory ability, about
2.9 additional years more than the strategy of local wound
care alone.14 In the ESRD population of the current
model, endovascular intervention produced 1.92 years of
ambulatory ability, only about 0.22 additional years (just
more than 2 additional months) more than the strategy
of local wound care alone. Therefore, compared with the
strategy of local wound care alone, endovascular interven-
tion cost $6960 per additional year of ambulation in the
general CLI population but $15,403 per additional year
of ambulation in the ESRD population.
Local wound care alone (“wound palliation”) with ma-
jor amputation as needed may be the next best option to
consider. There may be several potential beneﬁts of this
expectant form of management over primary amputation.
First among the beneﬁts might be the possibility of avoid-
ing the perioperative risks associated with ESRD. The peri-
operative mortality rate for patients with ESRD and CLI
undergoing surgical revascularization was 10.8% in a recent
American College of Surgeons National Surgical Quality
Improvement Project series,7 a strikingly high rate but
consistent with several single-center studies of this patient
population.3,8,9 In addition, local wound care may avoid
or at least delay the costs of limb loss, including an
impaired quality of life, functional limitations, and mone-
tary costs of long-term nursing care. The projections of
our model suggest that the strategy of wound palliation
may be associated with signiﬁcantly decreased total mone-
tary costs and improved functional status compared with
primary amputation; thus this strategy may be an option
to discuss in situations in which endovascular intervention
is not feasible.
There are several potential limitations to this analysis.
Whereas many studies have reported survival, limb salvage,
and patency rates for ESRD patients undergoing revascu-
larization, there are few data reported describing wound
healing rates speciﬁc to the ESRD patient population.
Although limb salvage rates are commonly reported,
wound healing is an important cost driver after revascular-
ization.14 Varying the post-revascularization wound heal-
ing rates that were assumed in this model did have an
impact on the results. At the assumed 1-year wound heal-
ing rate of 50% used in the base case scenario, endovascular
intervention had a reasonable cost-effectiveness ratio.
Below this rate, endovascular intervention would bemuch less appealing, whereas the possibility of cost-
savings (equal or better health outcomes at lower cost)
was not seen unless the 1-year wound healing rate
exceeded 65%, a scenario that we might submit is unlikely
in clinical practice in the ESRD patient population. More
data, however, are very much needed to further clarify
this point as very little currently exists.
Likewise, functional outcomes (namely, probability of
ambulating with a limb prosthesis) speciﬁc to an ESRD
patient population after major amputation have not been
described. Considering the high incidence of severe comor-
bidities in this patient population, it may be safe to assume
that functional outcomes after major amputation would be
worse in the ESRD population than in the general CLI
population. As the postamputation functional outcomes
of the ESRD population approach those of the general
CLI population, however, the beneﬁts of limb salvage at-
tempts decrease. This appears to be the reason that the
strategy of local wound care dominates endovascular inter-
vention (ie, becomes as beneﬁcial but at lower costs) as the
functional outcomes of the ESRD population approach
those assumed for the general CLI population in the ﬁrst
deterministic sensitivity analysis of the current study.
There are additional limitations posed by our method-
ology. As in the model of the general CLI population,14
the current model assumes a patient population that is
independently living and ambulatory at baseline and has
arterial disease that is amenable to effective treatment
with either endovascular or surgical revascularization. The
proportion of patients with ESRD, PAD, and nonhealing
foot wounds meeting these baseline assumptions is not
known. The ICERs in this study are done in a pairwise
fashion with local wound care as the comparator, however,
so eliminating some of the management strategies (for a
patient who does not have endovascular options, for
example) would not affect the estimates of ICERs. Finally,
as previously discussed,14 the clinical outcomes, functional
outcomes, and outpatient cost parameters used in this
model were based on a thorough review of previous litera-
ture.13 The inpatient cost estimates were obtained from
our single-center analysis using a transaction cost account-
ing system.14 Similar to generalizing the results of a ran-
domized trial or observational study, the extent to which
the ﬁndings of this model are generalizable at any given
medical center are therefore dependent on the extent
to which the given medical center has comparable clinical
outcomes, functional outcomes, and total costs (not
charges23).
Legislation in the United States has prohibited the in-
surers from making reimbursement decisions on the basis
of cost-utility analyses that assess cost per additional
quality-adjusted life-year as the primary measure of cost-
effectiveness.27 The current analysis has focused on cost
per additional year of ambulatory ability to use a patient-
centered functional outcome rather than quality-adjusted
life-years. At this time, there are no established or recom-
mended “thresholds” of cost per year of ambulation to
suggest when various interventions should or should not
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demonstrate some noteworthy themes that perhaps should
be considered in clinical practice, but we emphasize that
the decision of whether to proceed with any management
strategy should continue to be made on a patient-by-
patient basis. The decision should include discussion with
the patient and be inclusive of the preferences of the patient
for various outcomes as well as his or her acceptance of
various risks.
CONCLUSIONS
Endovascular intervention appears to be a cost-effective
alternative to local wound care alone for patients with
ESRD, PAD, and nonhealing foot wounds. Primary ampu-
tation does not appear to be a cost-effective option in this
patient population. More data are needed on the functional
outcomes and wound healing rates in patients with ESRD
and nonhealing foot wounds undergoing revascularization,
local wound care alone, and major amputations.
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Supplemental Fig (online only). Schematic diagram demonstrating the clinical states simulated in the probabilistic
Markov model. Hypothetical patients transition between the clinical states during the course of 10 1-year cycles. The
health beneﬁts and costs associated with each clinical state are accumulated during this time. (From Barshes NR,
Chambers JD, Cohen J, et al. Cost-effectiveness in the contemporary management of critical limb ischemia with tissue
loss. J Vasc Surg 2012;56:1015-24).
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